Baricitinib CAS 1187594-09-7

Baricitinib (CAS 1187594-09-7) Comprehensive Guide

Table of Contents

• Product Specifications & Comparative Analysis
• Therapeutic Applications & Mechanism
• Clinical Use Cases
• Customer Success Stories
• Supplier & Inquiry

Product Specifications & Comparative Analysis

Therapeutic Applications & Mechanism

Primary Indications:

• Moderate-to-severe rheumatoid arthritis (RA)
• Severe alopecia areata (AA)
• COVID-19 cytokine storm management (off-label)

Mechanism: Selective inhibition of JAK1/JAK2 kinases (IC₅₀ 5.7-5.9 nM), modulating IL-6, IFN-γ, and other pro-inflammatory cytokines.

Clinical Use Cases

Case Study 1: Adolescent Alopecia Areata (BRAVE-AA-PEDS Trial)
– 257 patients aged 12-18 with ≥89% scalp hair loss
– 36-week results (4 mg dose):
  • 42.4% achieved ≥80% scalp coverage (vs 4.5% placebo)
  • 36.5% achieved ≥90% coverage

Case Study 2: Rheumatoid Arthritis (RA-BEACON Trial)
– 527 MTX-IR patients
– 24-week results (4 mg dose):
  • ACR20 response: 55% vs 27% placebo
  • DAS28-CRP improvement: -1.8 vs -0.6

Customer Success Stories

Pharmaceutical Manufacturer A
– Requirement: 10 kg batch for Phase III trials
– Supplier: Hubei Yuanmeng Bio
– Outcome: 99.2% purity delivered within 4 weeks

Research Institute B
– Requirement: 50 mg analytical reference standard
– Supplier: Shanghai Chaolan Chemical
– Outcome: NMR/HPLC-MS certified material received in 72 hours

Supplier & Inquiry

Available Specifications:

For pricing, COA, or bulk inquiries:
Email: info@vivalr.com
Phone: (86) 15866781826